Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Fineline Cube Aug 3, 2026
Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Fineline Cube Aug 3, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Fineline Cube Aug 3, 2026
Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Policy / Regulatory

CDE Issues Guidelines for Real-World Drug Research and Evidence Framework

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) has released two important documents: the “Guiding Principles of...

Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Company Drug

Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study

Fineline Cube Feb 20, 2023

China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...

Company Deals

Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China

Fineline Cube Feb 20, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...

Company Deals

Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion

Fineline Cube Feb 20, 2023

China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with...

Company Deals R&D

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

Fineline Cube Feb 20, 2023

MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over...

Drug Policy / Regulatory

Zhejiang Suspends Generic Nesina Trading Due to IP Disputes

Fineline Cube Feb 20, 2023

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...

Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Company Deals Medical Device

Chunlizhengda to Acquire Majority Stake in Surgimaster for Medical Power Tools

Fineline Cube Feb 20, 2023

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a...

Company Deals

Duoning Biotech Secures Global Rights to Junzhen’s Cell Counter Products

Fineline Cube Feb 20, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm...

Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company Deals

Amcor Acquires Shanghai-Based MDK to Expand Asia-Pacific Footprint

Fineline Cube Feb 18, 2023

Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire...

Company Drug

CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Feb 17, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...

Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Posts pagination

1 … 597 598 599 … 702

Recent updates

  • BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway
  • China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions
  • Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab
  • AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Company Drug

Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.